In fact, many issues could influence the therapeutic effect of ICB treatment, including immune cell infiltration (Van Allen et al., 2015; Nishino et al., 2017), PD-L1 expression (Patel and Kurzrock 2015), tumor mutation burden (TMB) (Samstein et al., 2019), tumor antigen presentation (Snyder et al., 2014; Zaretsky et al., 2016) and so on. The gene discussed is CD274; the disease is neoplasm.